AVION PHARMS
SpecialtyAVION PHARMS is a specialty pharmaceutical company focused on Neurology. Key products include DHIVY.
AVION PHARMS's Key Drugs
AVION PHARMS's core commercial portfolio centers on DHIVY, BALCOLTRA, AVERI, spanning Neurology — its most strategically important drugs approved in the last 15 years.
AVION PHARMS's Recent FDA Approvals
New NDA/BLA approvals for AVION PHARMS over the last two years — novel drugs only, excluding generics and label supplements.
AVION PHARMS's Therapeutic Areas
AVION PHARMS's approved drugs and pipeline span 1 therapeutic area, led by Neurology, across 0 biologic and 3 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
AVION PHARMS's Top Competitors
AVION PHARMS's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
AVION PHARMS Pipeline Snapshot
Active clinical trials for AVION PHARMS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • DHIVY leads revenue
- • 3 key drugs tracked
Trial Catalysts
- • Neurology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling